Skip to main content

Table 3 Clinical/biochemical characteristics of NAFLD patients on diet and Orlistat treatment

From: Elevated endotoxin levels in non-alcoholic fatty liver disease

 

Diet alone

Diet and Orlistat

 

Baseline

6 months

12 months

Baseline

6 months

12 months

Age (years)

48.8 ± 11.5

  

53.4 ± 16

  

Body weight (kg)

100.0 ± 16.1

100.8 ± 16.3

101.6 ± 16.3

100.9 ± 24.5

95.5 ± 24.4 *

96.4 ± 25.7 *

Endotoxin (EU/mL)

15.9 ± 7.2

16.7 ± 5.5

14.4 ± 11.0

15.8 ± 4.6

14.4 ± 5.7

11.1 ± 4.0 **

sCD14 (μg/mL)

1.52 ± 0.40

2.46 ± 0.19

2.25 ± 1.28

1.45 ± 0.60

1.55 ± 0.35

1.59 ± 0.69

Glucose (mmol/L)

6.5 ± 2.4

6.1 ± 1.7

8.2 ± 3.8

5.6 ± 0.9

5.3 ± 0.7

5.4 ± 1.4

Insulin (μU/mL)

24.2 ± 20.2

 

21.2 ± 9.5

22.6 ± 13.5

 

21.6 ± 13.1

HOMA-IR

3.2 ± 2.6

 

3.0 ± 1.3

2.9 ± 1.8

 

2.8 ± 1.6

ALT (U/L)

129 ± 86

90 ± 67

100 ± 68

93 ± 31

60 ± 20 **

66 ± 41

Cholesterol (mmol/L)

4.9 ± 0.8

4.8 ± 1.4

4.7 ± 1.1

5.1 ± 1.4

4.6 ± 1.6

4.9 ± 1.7

LDL-cholesterol (mmol/L)

2.8 ± 0.8

3.0 ± 1.2

2.8 ± 1.0

3.1 ± 1.3

2.7 ± 1.4

2.8 ± 1.6

HDL-cholesterol (mmol/L)

1.09 ± 0.17

1.62 ± 0.58

1.68 ± 1.35

1.16 ± 0.26

1.38 ± 0.39

1.23 ± 0.36

Triglycerides (mmol/L)

2.4 ± 1.3

2.3 ± 1.0

2.4 ± 1.6

1.9 ± 0.6

1.7 ± 0.6

1.9 ± 0.7

  1. NAFLD patients underwent a 12 month course of intensive diet-treatment with (n = 8) or without) Orlistat (n = 6). Data are mean (± SD). * p < 0.005 (versus baseline), ** p < 0.05 (versus baseline).
Back to article page

Journal of Inflammation

ISSN: 1476-9255

Contact us